

2019

## Managing anxiety disorders in adults

Gregory Wilkins

*The University of Notre Dame Australia*, [greg.wilkins@nd.edu.au](mailto:greg.wilkins@nd.edu.au)

Gavin Andrews

Caroline Bell

Philip Boyce

Christopher Gale

*See next page for additional authors*

Follow this and additional works at: [https://researchonline.nd.edu.au/med\\_article](https://researchonline.nd.edu.au/med_article)



This article was originally published as:

Wilkins, G., Andrews, G., Bell, C., Boyce, P., Gale, C., Rapee, R., & Lampe, L. (2019). Managing anxiety disorders in adults. *Medicine Today*, 20 (12), 12-22.

Original article available here:

<https://medicinetoday.com.au/2019/december/feature-article/managing-anxiety-disorders-adults>

This article is posted on ResearchOnline@ND at  
[https://researchonline.nd.edu.au/med\\_article/1162](https://researchonline.nd.edu.au/med_article/1162). For more  
information, please contact [researchonline@nd.edu.au](mailto:researchonline@nd.edu.au).



---

**Authors**

Gregory Wilkins, Gavin Andrews, Caroline Bell, Philip Boyce, Christopher Gale, Ronald Rapee, and Lisa Lampe

This article originally published: -

Wilkins, G., Andrews, G., Bell, C., Boyce, P., Gale, C., Rapee, R., and Lampe, L. (2019)  
Managing anxiety disorders in adults. *Medicine Today*, 20(12): 12-22.

Permission granted by Medicine Today for use on ResearchOnline@ND.

© Medicine Today 2016 (<http://www.medicinetoday.com.au>).

# Managing anxiety disorders in adults

**GREGORY WILKINS** BMed(Hons), FRANZCP; **GAVIN ANDREWS** MD, FRCPsych, FRANZCP

**CAROLINE BELL** BM BCh, MA, MRCPsych, MD

**PHILIP BOYCE** MB BS, MD, FRANZCP; **CHRISTOPHER GALE** MB BS, MD, FRANZCP

**RONALD RAPEE** PhD(Psychology), MS(Psychology), BS(Psychology)

**LISA LAMPE** MB BS, PhD, FRANZCP

**The GP has a key role in identifying patients presenting with anxiety symptoms and ensuring appropriate acute and long-term management. There are two key messages for GPs to follow: once you have made a diagnosis of an anxiety disorder, tell the patient you have a treatment for it. Second, do not let your anxiety lead you to prescribe inappropriately or overinvestigate for all possible differential diagnoses.**

**A**nxiety disorders, like all mental disorders, lie on a spectrum that extends from normal anxiety to transient symptoms, through to severe and disabling symptoms that can persist for years. The specific thoughts and behaviours that characterise each of the anxiety disorders are covered in the RANZCP Clinical Practice Guidelines for anxiety disorder.<sup>1</sup> These disorders include

variants of excessive worry, acute attacks of anxiety or panic and avoidance of anxiety-provoking situations.

Panic disorder, social anxiety disorder (SAD) and generalised anxiety disorder (GAD) are the most common anxiety disorders in Australia and New Zealand. Obsessive compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) have been moved out of the DSM-5 chapter

**Medicine**Today 2019; 20(12): 12-22

Dr Wilkins is a Consultant Psychiatrist in private practice and a tutor at the School of Medicine, University of Notre Dame, Sydney. Professor Andrews is Emeritus Professor of Psychiatry at UNSW; and 2018 retired Director of Clinical Research Unit for Anxiety and Depression, UNSW Sydney School of Psychiatry, St Vincent's Hospital, Sydney. Associate Professor Bell is Associate Professor in the Department of Psychological Medicine, University of Otago, Christchurch. Professor Boyce is Professor of Psychiatry at The University of Sydney, Sydney. Dr Gale is a Consultant Psychiatrist and Senior Lecturer in the Department of Psychological Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand. Professor Rapee is a Distinguished Professor of Psychology; ARC Laureate Fellow; and Founding Director of the Centre for Emotional Health, Department of Psychology, Macquarie University, Sydney. Associate Professor Lampe is Discipline Lead and Psychiatry Program Convenor for the Joint Medical Program (BMedSc/MD), School of Medicine and Public Health, University of Newcastle, Newcastle, NSW. All authors were members of the 2018 RANZCP Clinical Practice Guidelines Team for Panic Disorder, Social Anxiety Disorder and Generalised Anxiety Disorder, Melbourne, Vic.



on anxiety disorders and placed in their own categories of 'Obsessive compulsive and related disorders', and 'Trauma and stressor-related disorders', respectively.

The systematic implementation of anxiety disorder guidelines has been shown to result in earlier treatment gains and shorter treatment times.<sup>2</sup> This article draws from the RANZCP guidelines to



© RAPIDEYE/ISTOCKPHOTO.COM  
MODEL USED FOR ILLUSTRATIVE PURPOSES ONLY

focus on the use of psychological treatments and pharmacotherapy to treat panic disorder, SAD and GAD, for which there is considerable evidence of efficacy. The key features of these anxiety disorders are presented in Table 1. This article also provides practical clinical guidance on cognitive behavioural therapy (CBT) as the principal psychological treatment for

the anxiety disorders as it has the most extensive evidence base for its efficacy. Furthermore, it is available online, allowing easy and extensive dissemination. The selective serotonin reuptake inhibitor (SSRI) and serotonin and noradrenaline reuptake inhibitor (SNRI) antidepressants are also covered because the evidence base of benefit is larger, the side effect profile

## KEY POINTS

- Management of anxiety disorder requires a biopsychosocial and lifestyle approach.
- Anxiety disorders are common and often disabling but are under-recognised and often poorly treated in clinical practice.
- Effective first-line treatments are cognitive behavioural therapy (CBT), either face-to-face or digitally delivered (dCBT), and the serotonergic antidepressants.
- No matter what treatment is selected, it is likely to take four to six weeks to begin to show an effect.
- Functional recovery is the goal and is achievable through effective use of evidence-based treatments.
- Use of evidence-based clinical practice guidelines for treatment has been shown to result in better outcomes.

is better, and the experience of practitioners is wider than with other classes of medication, especially the older, or first generation, antidepressants.

## Factors contributing to the onset of anxiety disorders

Anxiety disorders arise from a combination of vulnerable personality traits, early life stressors and psychosocial adversity (for example, lack of support, hardship, dysfunctional relationships) and are often triggered by stressful significant life events (such as the death of a loved one, an illness, childbirth or workplace bullying). Temperamental traits, with a moderate level of heritability (such as neuroticism or negative emotionality), are important vulnerability factors for anxiety; neuroticism, in particular, seems to confer greater vulnerability to how an individual responds to psychological distress, which may precipitate an anxiety disorder in the context of environmental or interpersonal stressors.

**TABLE 1. KEY FEATURES OF SPECIFIC ANXIETY DISORDERS**

Panic disorder	Sudden attacks of fear or anxiety (usually brief, but which may be so severe that the person thinks they might collapse or die), concern about the attacks recurring, and avoidance of or marked distress in situations in which they might recur.
Social anxiety disorder (SAD)	Fear and avoidance of situations where the person thinks they might be the centre of attention; concern about doing or saying something embarrassing, and that others might notice the anxiety and be critical.
Generalised anxiety disorder (GAD)	Months of excessive worry over everyday things, avoiding or seeking reassurance about situations when the outcome is uncertain, and being overly concerned about things that could go wrong. Worry is experienced as excessive and difficult to control and results in fatigue, poor sleep and feeling on edge much of the time.

**TABLE 2. 12-MONTH PREVALENCE OF ANXIETY DISORDERS IN AUSTRALIA AND NEW ZEALAND<sup>8,9</sup>**

	Australia	New Zealand
Panic disorder	2.6%	1.7%
Social anxiety disorder (SAD)	4.7%	5.1%
Generalised anxiety disorder (GAD)	2.7%	2%
Any anxiety disorder (including PTSD and OCD)*	14.4%	14.8%
Agoraphobia without panic	2.8%	0.6%

Abbreviations: OCD= obsessive-compulsive disorder; PTSD = post-traumatic stress disorder.

\* OCD and PTSD have since been moved out of the DSM-5 chapter on anxiety disorders and placed in their own categories of 'Obsessive compulsive and related disorders', and 'Trauma and stressor-related disorders', respectively.

**TABLE 3. MEAN AGE OF ONSET OF ANXIETY DISORDERS<sup>8,9</sup>**

	Australia	New Zealand
Panic disorder	30 years	24 years
Social anxiety disorder (SAD)	13 years	12 years
Generalised anxiety disorder (GAD)	33 years	32 years
Agoraphobia without panic	22 years	No available data

Substance use and misuse (including over-the-counter medications, herbal medications and intoxication) or withdrawal are often missed as a cause of anxiety, hence it is important to screen for these.

**Prevalence, cost and functional impact**

Anxiety disorders, as conceptualised in previous classification systems such as DSM-IV (that included OCD and PTSD as anxiety disorders), form the most

common class of mental disorders.<sup>3-6</sup> The second Australian Survey of Mental Health and Wellbeing, based on the DSM-IV, estimated that one in seven adults (14.4% of the population) experienced an anxiety disorder in the past 12 months. A very similar rate (14.8%) was estimated in New Zealand.<sup>7,8</sup> SAD is the most prevalent anxiety disorder, followed by GAD and panic disorder/agoraphobia (Table 2).<sup>8,9</sup> Anxiety disorders are more common in women than men; in people who are separated,

divorced or widowed; and those who are less educated or unemployed. Demographic status may be both a consequence and a cause of anxiety disorders.<sup>10</sup>

Anxiety disorders are associated with high levels of distress, disability and service use.<sup>10</sup> In the second Australian Survey of Mental Health and Wellbeing, in people who met criteria for an anxiety disorder, about half reported an inability to work or do normal tasks for less than one day during the previous month because of anxiety, a third reported one to seven days and one-sixth reported more than seven days.

**Onset and course**

Anxiety disorders typically start early in life (Table 3), and prevalence declines with age.<sup>7,11</sup> Developing an anxiety disorder after the age of 40 years is uncommon, and so when a person over 40 presents with an initial onset of an anxiety disorder, alternative causes of anxiety such as mood disorders, alcohol and substance use disorders, trauma, physical illness or its treatment should be considered.<sup>9,10</sup>

Panic disorder often follows a waxing and waning course with periods of increased anxiety (characterised by worsening or episodic flares of symptoms) and periods of remission in between. Some experience a fluctuating course with exacerbations that are often precipitated by life-event stress, excess caffeine, sleep disruption, physical illness or hormonal changes, whereas others have a more chronic course. Only a minority have complete, sustained remission without relapse.<sup>12-14</sup>

SAD is usually a chronic disorder. Periods of remission are most common in milder, nongeneralised SAD, in nonclinical patients, and in those with fewer social fears.<sup>15-17</sup> The US National Comorbidity Survey Replication estimates that only 20 to 40% of people with SAD recover within 20 years of onset and only 40 to 60% recover within 40 years.<sup>16</sup>

GAD is a chronic disorder that can be exacerbated by stressful life events. Most

**TABLE 4. PATTERN AND OUTCOME OF ANXIETY DISORDERS**

	Pattern of disorder	Outcome
Panic disorder	<ul style="list-style-type: none"> <li>• Chronic course OR a waxing and waning course</li> <li>• Remission of symptoms in between episodic flares</li> <li>• Often precipitated by life event stress</li> </ul>	<ul style="list-style-type: none"> <li>• Only a small minority have complete, sustained remission without relapse</li> </ul>
Social anxiety disorder (SAD)	<ul style="list-style-type: none"> <li>• Chronic</li> <li>• Periods of remission in milder cases, nongeneralised SAD and those with fewer social fears</li> </ul>	<ul style="list-style-type: none"> <li>• 20 to 40% recover within 20 years</li> <li>• 40 to 60% recover within 40 years</li> </ul>
Generalised anxiety disorder (GAD)	<ul style="list-style-type: none"> <li>• Chronic disorder exacerbated by stressful life events</li> </ul>	<ul style="list-style-type: none"> <li>• Most patients are still affected after 10 years, and half of those who remit will relapse</li> </ul>

patients are still affected after 10 years, and half of those who remit will relapse (Table 4).<sup>18,19</sup>

### Service use

It is estimated that less than half of people with anxiety disorders seek treatment from a health professional. Those who do seek treatment commonly attend primary care, where anxiety is largely under-recognised.<sup>20</sup> Only 30 to 60% of people who see their GP for an anxiety disorder receive a treatment regarded as adequate<sup>9,21</sup> and Australian data suggest that overall, only a third of treatment-seekers receive minimally adequate treatment, with the rest receiving counselling or inadequate advice.<sup>22,23</sup>

People with panic disorder seek help more frequently, often from medical specialists or emergency departments, probably because of concerns about their physical symptoms.<sup>24-27</sup> They are sometimes referred for unnecessary investigations to rule out possible medical causes for the symptoms.

### Comorbidity

There are high rates of comorbidity between anxiety disorders and depressive disorders. Most patients seen in a clinical psychiatric practice will meet criteria for

more than one mental disorder, and this comorbidity is associated with most disability days and consultations due to mental disorders.<sup>28-30</sup> Comorbidity should be routinely assessed, as it is an indicator of increased functional impairment and economic costs.<sup>29,31-33</sup>

Comorbidity has been associated with a slower rate of recovery and a poorer response during active treatment. However, the presence of comorbidity should not lead to undue pessimism about the value of treatment and prospects for eventual recovery, since both antidepressant medication and CBT may still be effective.<sup>34,35</sup>

Overall, medical comorbidity across anxiety disorders is not associated with poorer outcomes;<sup>36</sup> and several studies have shown that people with or without comorbid disorders respond similarly to face-to-face CBT and digitally-delivered CBT (dCBT).<sup>37-39</sup>

### Suicide risk

People with anxiety disorders have an increased risk of suicidal ideation and attempts, especially when comorbid with depression. All patients with anxiety disorders should be assessed for suicidal thinking, risk of self-harm and the presence of comorbid depression.

## 1. WHEN TO SUSPECT OR LOOK FOR AN ANXIETY DISORDER

Suspect that an anxiety-related condition requiring further assessment is present in the following patient presentations:

- unusually persistent anxiety for at least six months, together with a reported sense of urgency, impending doom, apprehension, nervousness, or feeling on edge. Also, patients may report accompanying feelings of restlessness, irritability, fatigue or tension
- inability to stop or control worrying thoughts for more than half the days of the past six months
- excessive shyness, sensitivity, social withdrawal or embarrassment beyond that expected in this setting of visiting the GP
- occurrence of a panic attack – an abrupt surge of intense fear or discomfort that reaches a peak within minutes. The person often feels that they must do something urgently (e.g. escape to a safer place)
- medically unexplained symptoms such as chest pain, rapid heart rate, sweats or tremor
- panic symptoms, which may occur across different types of anxiety disorders such as social phobia, specific phobia or trauma. They may also arise in association with a known or unrecognised medical condition, hence the importance of screening for medical disorders (see Box 3)

### Assessing patients presenting with an anxiety disorder

When a patient presents with a suspected anxiety disorder (Box 1), a comprehensive assessment to obtain as much relevant information as possible is essential to providing an optimal treatment plan (Box 2). The aims of the assessment are to:

- establish a good therapeutic relationship with the patient
- develop a detailed biopsychosocial and lifestyle formulation
- consider differential diagnoses and establish a primary diagnosis

## 2. COMPREHENSIVE ASSESSMENT OF PATIENTS PRESENTING WITH AN ANXIETY DISORDER

### Comprehensive assessment

Obtain information about the following:

- the nature, severity and duration of symptoms, avoidance behaviours and use of safety behaviours (i.e. behaviours that patients carry out during attacks of anxiety in the belief that it will prevent the feared catastrophes)
- the degree of distress and functional impairment
- the presence of comorbid anxiety or mood disorders, personality disorders, substance use (including tobacco, illicit substances, prescribed and over-the-counter medications and other substances such as caffeine and energy drinks), and medical conditions (See Box 3)
- personal and family history of mental health disorders, and personal history of chronic health problems, domestic violence or sexual abuse
- experience of, and response to, past treatments, including therapeutic response and adverse effects
- the quality of interpersonal relationships and social support networks, living conditions, social isolation, employment status including work environment, and immigration status
- safety, including suicide risk
- medical evaluation including system review and appropriate physical examination and blood tests including, at a minimum, thyroid function tests, electrolytes, full blood count and blood glucose level, ECG if there are cardiac symptoms or a relevant family history (e.g. arrhythmias). Further investigations should be guided by the patient's presentation, such as unusual symptoms or onset after the age of 40 years.

### More specific information to guide diagnosis and treatment planning

- the underlying threat or danger that the patient is expecting (what negative outcome/s do they fear)
- physiological symptoms and beliefs about somatic symptoms (e.g. pounding heart that the patient fears may herald a heart attack)
- behavioural and cognitive responses to anxiety (e.g. avoidance, worry, reassurance-seeking, safety behaviours) (see Table 5)
- precipitants (triggers) for anxiety and avoidance

- identify comorbid disorders that may affect treatment and outcome and assist treatment planning
- assess psychosocial and lifestyle factors that could help or hinder the recovery process
- assess the capacity of the patient to benefit from self-help material independent of the clinician (for example, ask about digital competence, possibly indicated by social media and other online activity). Most cases of anxiety disorder are likely to be diagnosed by a GP, but in cases of uncertainty, a second opinion from a psychiatrist or clinical psychologist may be helpful.

### Differentiating anxiety disorders

One of the most important ways of differentiating between anxiety disorders is to examine the associated cognitions. People with panic disorder worry that their panic will result in physical or mental harm to themselves, people with SAD worry that they will be judged negatively, and those with GAD worry excessively across a variety of contexts (Table 1). Importantly, panic attacks can occur in any anxiety disorder (including specific phobias), whereas OCD and PTSD occur when people are confronted by their feared or triggering situation. Being anxious a lot of the time is not synonymous with GAD as there are specific concerns and

features that are required for a clinical diagnosis of GAD. There is a range of self-report measures that can assist with symptom assessment and monitoring (Box 4).<sup>40-59</sup>

### Treatment

These guidelines recommend a pragmatic approach to selecting therapy in collaboration with the patient, beginning with psychoeducation and advice on lifestyle factors, followed by specific treatment.

Selection of treatment should be based on:

- evidence of efficacy
- patient preference
- accessibility
- cost
- tolerability
- safety
- consideration of symptom severity and comorbidity.

If symptoms are mild, transient and without associated impairment in social and occupational function, patients may not require treatment.<sup>60</sup> In such cases, reassurance, psychoeducation and review may be the most appropriate approach.

If symptoms are impairing the patient's ability to function, recommended initial treatment options include:

- CBT, delivered face-to-face or digitally, using a smartphone, tablet or computer (dCBT)
- medication with an SSRI (or an SNRI if SSRIs are ineffective or not tolerated), accompanied by instructions for graded exposure to anxiety triggers
- a combination of CBT and medication.

The choice of treatment should be made in collaboration with the patient, taking into consideration patient preference and prior responses to treatment, with one proviso: that people with severe anxiety disorders or severe comorbid major depression be advised to consider a combination of antidepressant medication and CBT. When possible, the patient's family or significant others



### 3. COMMON MEDICAL CONDITIONS ASSOCIATED WITH PANIC ATTACKS OR PANIC-LIKE SYMPTOMS

#### Substance-induced

- Intoxication (e.g. stimulants)
- Adverse effects of over-the-counter medications (e.g. decongestants, beta-adrenergic inhalers, stimulants)
- Effects of caffeine-related products (e.g. coffee, energy drinks/supplements)
- Withdrawal (e.g. alcohol, benzodiazepines)

#### Medical conditions

##### More clinically relevant

- Hyperthyroidism and (less common) hypothyroidism
- Cardiac arrhythmias
- Vestibular dysfunction
- Seizure disorders (e.g. complex partial seizures)
- Hypoglycaemia

##### Less clinically relevant

- Hypoparathyroidism and hyperparathyroidism
- Pheochromocytoma
- Pulmonary embolus
- Electrolyte disturbance
- Cushing's syndrome
- Menopause/oestrogen deficiency

**TABLE 5. KEY COGNITIVE SYMPTOMS AND MEASURES TO AID IN DIAGNOSIS**

Consider	Ask about	Self-report measure*
Panic disorder	Concern about panic outcomes i.e. that the severity of the anxiety will cause a heart attack, collapse, loss of control or death	PDSS-SR
Social anxiety disorder (SAD)	Concern about negative evaluation i.e. that they will embarrass themselves, or that others will think badly of them (use Mini-SPIN self-report measure to screen; SPS and SIAS as symptom measures)	Mini-SPIN SPS/SIAS
Generalised anxiety disorder (GAD)	Excessive and uncontrollable worry about everyday things, and concern that if they do not attend to the worries then the outcome will be bad	GAD-7 or PSWQ-3
Specific phobia	Persistent and excessive fear of a particular object or situation (e.g. animals, heights, enclosed spaces, injections, seeing blood)	FSS-II
Obsessive compulsive disorder	Worries about harming someone, contamination, blasphemy, sexually deviant behaviour and related images, impulses, urges	OCI-ROK
Post-traumatic stress disorder	Intrusive memories of a past trauma (nightmares, flashbacks) that cause distress and avoidance of situations that could trigger the memories	PCL-C
Separation anxiety disorder	Concern about being separated from home or attachment figure	ASA-27
Illness anxiety disorder	Concern about having a serious physical illness	SHAI
Major depressive disorder (MDD)	Low mood, anhedonia, past-oriented rumination (e.g. 'Why did I allow that to happen?') and MDD symptoms (e.g. sadness, loss of interest, worthlessness)	Item 9 of PHQ-9 indicates suicide risk

\* See Box 4 for a full list of self-report measures.

should be involved in management planning decisions and in supporting the patient through their treatment. Despite the frequent use of CBT and pharmacotherapy for anxiety disorders in clinical practice, there is currently limited evidence to support routine use of this combination.

### Cognitive behavioural therapy

At the simplest level, CBT helps patients recognise and change the dysfunctional thoughts, emotions and behaviours that are part of the fear and avoidance that typify and maintain their disorder. CBT is a skills-based approach that consists of psychoeducation about the nature and maintenance of anxiety, providing skills

in identifying and challenging anxious thoughts and repeated and graded exposure to feared or avoided stimuli (situations, sensations or thoughts).

CBT can be delivered face-to-face (individual or group), digitally, or through self-guided CBT books for patients (self-help books). Face-to-face delivery of CBT, particularly individual therapy, has been the most extensively studied with its efficacy supported by meta-analyses.<sup>61</sup> CBT has been manualised for therapists and patients, and CBT manuals can be digitised.<sup>62-64</sup> Benefiting from CBT, whether face-to-face or online, requires the patient to practise their skills regularly.

Face-to-face CBT is effective, especially when conducted by a trained clinical psychologist, and is as or more acceptable than digital help or self-help methods. However, it is much less accessible, and there is a risk of loss of fidelity, that is, a risk that the treatment delivered may not include all the elements of the treatment package that research has shown to be effective. Digital CBT and self-help have fidelity and are more accessible and may be as effective but are not acceptable for some.

Psychotherapy is generally less associated with side effects than pharmacotherapy. Pharmacotherapy can be

#### 4. SELF-REPORT MEASURES FOR ASSESSMENT AND DIFFERENTIAL DIAGNOSIS

**ACQ:** Agoraphobic Cognitions Questionnaire<sup>40</sup>

**ASA-27:** Adult Separation Anxiety Questionnaire<sup>41</sup>

**ASI:** Anxiety Sensitivity Index<sup>42</sup>

**DCQ:** Dysmorphic Concern Questionnaire<sup>43</sup>

**EDI-3SC:** Eating Disorder Inventory-3 Symptom Checklist<sup>44</sup>

**FSS-II Fear:** Survey Schedule II<sup>45</sup>

**GAD-7:** Generalised Anxiety Disorder-7<sup>46</sup>

**MI:** The Mobility Inventory for Agoraphobia<sup>47</sup>

**Mini-SPIN:** Mini-Social Phobia Inventory<sup>48</sup>

**OCI-R:** Obsessive Compulsive Inventory – Revised<sup>49</sup>

**PAS:** Panic and Agoraphobia Scale<sup>50</sup>

**PCL-C:** PTSD Checklist Civilian Form<sup>51</sup>

**PDSS-SR:** Panic Disorder Severity Scale<sup>52</sup>

**PHQ-9:** Patient Health Questionnaire-9<sup>53</sup>

**PSWQ-3:** Penn State Worry Questionnaire-3<sup>54</sup>

**SHAI:** Short Health Anxiety Inventory<sup>55</sup>

**SPS/SIAS:** Social Phobia Scale/Social Interaction Anxiety Scale<sup>56</sup>

**PCL-5:** PTSD Checklist Civilian Form for DSM 5<sup>57-59</sup>

associated with adherence problems, but medications are usually accessible. The direct financial costs to the patient are highest with any face-to-face intervention, i.e. talking therapy or medication.

It is likely that some patients will only respond to CBT and others only to antidepressants. Therefore, persisting with either when there is no response may not be beneficial, and switching to the alternative may be more productive.<sup>65-68</sup>

#### Medications

The advantages of pharmacotherapy are that the recommended medications are easily prescribed in primary care, they are widely available at relatively low cost, and

the quality of medicines is assured. Antidepressants, especially the SSRIs and, to a lesser extent, the SNRIs, are the first-line medications for panic disorder, SAD and GAD based on evidence from placebo-controlled randomised controlled trials, overall safety and low misuse potential.<sup>69,70</sup> Pharmacotherapy for anxiety disorders should always be accompanied by instructions for graded exposure to feared situations.

**Antidepressants, especially the SSRIs and, to a lesser extent, the SNRIs, are the first-line medications for panic disorder, SAD and GAD**

#### SSRI and SNRI antidepressants

For about half of the participants in clinical trials of SSRIs or SNRIs, symptoms improve to the point that they no longer meet criteria for the disorder. Disability decreases and quality of life improves. Although the tolerability profiles of SSRIs and SNRIs in patients with anxiety disorders are not fully established, systematic reviews of studies in depressed patients suggest that duloxetine and venlafaxine may be less well tolerated than the SSRIs.<sup>71,72</sup> Overall, the evidence does not indicate that any one of these medications be preferred over another and selection should be made based on previous success with the individual patient, patient preference, and clinician familiarity with the medication.

SSRI and SNRI antidepressants can have adverse effects including initial exacerbation of anxiety (particularly where there is a history of panic attacks), nausea, headache, sleep disruption and sexual dysfunction. It is important to be aware that people with anxiety disorders, particularly those with panic disorder, are very aware of and concerned about bodily symptoms. They should receive careful education about likely adverse effects if prescribed SSRI and SNRI

antidepressants and be warned that adverse side effects usually occur early in treatment before benefits are seen, and these side effects usually settle. In younger people, there has been an association of SSRIs with suicidal thoughts, but not completed suicide.<sup>73,74</sup> Clinicians should therefore use caution in prescribing any antidepressant in childhood or early adolescence.

#### Dosing of SSRIs and SNRIs

To reduce the likelihood and severity of side effects, and the risk of exacerbating anxiety, it is advisable to start treatment with antidepressants at a low dose (about half of the starting dose given to depressed patients) and to titrate slowly, increasing the dose as tolerated to therapeutic effect. Patients should be advised to take the medication daily as prescribed, not just when they feel anxious, and that it can take up to six weeks to feel a benefit from the medication, or even up to 12 weeks to experience the full benefit.

There is inconsistent evidence for a dose-response relationship; however, some patients who have not responded to a lower dose may respond to a higher dose within the therapeutic dose range. Little evidence is available to guide the duration of treatment. If the desired response is achieved, the medication should be continued for 12 months. Discontinuation should be gradual, for example, over three to four months to minimise discontinuation symptoms or withdrawal syndrome.

#### Other antidepressant classes

Tricyclic antidepressants (TCAs) have demonstrated efficacy in the treatment of panic disorder and GAD, but they are associated with more side effects, poorer tolerability and toxicity in overdose. TCAs should be reserved for patients who have not responded to, or are unable to tolerate, SSRIs and SNRIs. Abrupt discontinuation of TCAs may cause similar symptoms as well as lead to cholinergic rebound.<sup>75</sup>

---

The irreversible monoamine oxidase inhibitors (MAOIs) have proven efficacy in SAD and panic disorder. However, their use in the treatment of these disorders has been limited because of serious potential adverse effects, the need for dietary restrictions, toxicity in overdose and important pharmacokinetic interactions; referral to a psychiatrist to prescribe MAOIs is advisable.

Moclobemide, a reversible inhibitor of monoamine oxidase A (RIMA), has been shown to be modestly effective in the treatment of SAD, and there is limited evidence that it is effective in the treatment of panic disorder. Doses of RIMA up to the recommended maximum dose do not require dietary restriction. Above this dose, dietary restrictions will be necessary for foods containing tyramine.

Very few studies have evaluated mir-tazapine in the treatment of anxiety disorders, but it is used by some clinicians. There is some evidence to support the use of agomelatine in GAD, but not the other anxiety disorders.<sup>76</sup>

#### ***Drug-drug interactions with antidepressants***

Interactions with other drugs can occur because of pharmacokinetic or pharmacodynamic effects. Prescribers are strongly advised to check for the risk of interactions when prescribing for a patient who is taking other medications.<sup>77</sup>

#### ***Stopping and switching antidepressants***

When ceasing some SSRIs and SNRIs (especially paroxetine and venlafaxine),

many individuals experience a withdrawal syndrome, with flu-like symptoms, shock-like sensations, dizziness, insomnia, vivid dreams, irritability and crying spells, as well as excessive sweating and myalgia. Fluoxetine and its metabolite have a very long half-life, which means that discontinuation symptoms are unlikely, but this also means that a washout period of five weeks is required before changing to another antidepressant or other medication.

#### ***Benzodiazepines***

Benzodiazepines have well established anxiolytic effects, but there is concern about their use because of adverse effects, (including cognitive impairment, falls, and sedation) tolerance and dependence.<sup>78</sup> Their use can undermine the effectiveness

## 5. MANAGEMENT OF PATIENTS EXHIBITING SIGNIFICANT DISTRESS FROM ACUTE ANXIETY

If a patient presents with acute anxiety, it is important to:

- establish if the patient is posing a threat to themselves or others
- establish if a psychiatric consultation is required as a matter of urgency
- ideally, assess the patient in a calm, safe environment with their consent, and introduce social support from appropriately informed family or friends present
- assist as above with appropriate professional staff present (mental health worker or nurse)

Initial management and containment of risk for first presentation patients with acute severe anxiety requires the GP to listen to the patient's concerns. These include:

- careful history taking to establish a time course and any/all relevant factors
- providing an appropriate explanation to the patient of their condition and the proposed management
- initiating behavioural management of their symptoms
- teaching slow-breathing exercises if the patient is hyperventilating
- providing a fast-acting anxiolytic agent if necessary
- admission to a facility for inpatient care in cases where the patient is suicidal or when the anxiety cannot be contained for a patient with limited supports
- outpatient care with a responsible adult
- appropriate monitoring, review and follow up

of CBT by becoming a safety behaviour when patients see taking a benzodiazepine as their main source of relief. Such a belief may present a barrier to considering other means of managing their anxiety in patients with panic disorder and SAD. Because of these concerns, benzodiazepines should not be used as first-line agents, but be reserved for patients whose

symptoms have not responded to other treatments. There is also potential for abuse of benzodiazepines and, although it is difficult to predict which patients will develop long-term problems, benzodiazepines should be avoided in those with a previous or current history of substance abuse.<sup>79</sup>


Benzodiazepines may have a favourable safety profile in the management of treatment-refractory anxiety disorders, compared with atypical antipsychotic agents.

Benzodiazepines are not recommended routinely when commencing patients on SSRIs – slow titration and frequent review in the early stages of treatment will enable most patients to start SSRIs without significant worsening of their anxiety.

**An increase in alertness and anxiety facilitates problem-solving, whereas severe anxiety impairs the ability to problem-solve and can be debilitating**

### Follow-up and monitoring

The onset of beneficial effects typically occurs 4 to 6 weeks after starting treatment with either CBT or medication. GPs should initially see the patient weekly to monitor adherence and adverse effects, to identify any exacerbation of symptoms until there is a response and symptoms have stabilised, and to listen to any concerns or anxieties the patient has regarding treatment (the latter builds and strengthens the connection with the patient that in turn will enhance the efficacy of treatment). The effectiveness of treatment should be reviewed after four to six sessions of weekly CBT or after four to six weeks of pharmacotherapy with advice on graded exposure to feared situations. Rating scales (Box 4 and Table 5) can be used to monitor change and are often helpful for both patients and GPs.



**Figure.** The Hebbian version of the Yerkes-Dodson Law demonstrating the relationship between anxiety and performance.

Adapted from Yerkes RM, Dodson JD (1908) and Hebb DO. (1955).<sup>80,81</sup>

### Education

All patients should be educated about anxiety, especially the adaptive aspects; an increase in alertness and anxiety facilitates problem-solving, whereas severe anxiety impairs the ability to problem-solve and can be debilitating (Yerkes-Dodson curve; Figure).<sup>80,81</sup> This information is extremely beneficial because the patient often feels that what they have been experiencing is frightening and unique to them. Education about managing anxiety involves outlining fear-reinforcement cycles to the patient as an explanation for why anxiety has persisted and the need to eventually confront what is feared.

Educating patients also includes the promotion of healthy lifestyle behaviours including healthy eating, good sleep, regular exercise and reduced use of caffeine, tobacco and alcohol. Reliable, plain-language information for patients is available online ([www.yourhealthinmind.org](http://www.yourhealthinmind.org)).

### What can GPs do to help someone who is acutely anxious?

In patients experiencing acute anxiety, just sitting in the waiting room often helps to reduce symptoms because they know that a doctor is near. However, if they are hyperventilating severely and do not respond to reassurance, they can be guided through a slow-breathing technique, in which they are instructed to take light (not deep) breaths in and out over cycles of about

**6. ONLINE RESOURCES AVAILABLE IN AUSTRALIA AND NEW ZEALAND**

**Online resources**

The Black Dog Institute maintains a list of organisations that provide online resources for wellbeing and common mental disorders ([www.emhprac.org.au/services](http://www.emhprac.org.au/services)). Some 80 organisations offer a wide range of services. Three of the organisations listed have replicated randomised controlled trials establishing the efficacy of their services concerning the disorders covered in the clinical practice guidelines<sup>1</sup>:

- **Mental Health Online**  
([www.mentalhealthonline.org.au](http://www.mentalhealthonline.org.au)) for panic disorder
- **MoodGYM**  
(<https://moodgym.com.au>) for generalised anxiety disorder (GAD)
- **This Way Up**  
(<https://thiswayup.org.au>) for panic disorder, social anxiety disorder and GAD

**Digital cognitive behavioural therapy programs**

Digital cognitive behavioural therapy (dCBT) programs that are effective in practice for people with mixed or comorbid anxiety and depressive disorders are available at:

- **Mind Spot**  
(<https://mindspot.org.au>)
- **This Way Up**  
(<https://thiswayup.org.au>)

These websites are preferred when recommending dCBT.

six-seconds. It is likely to take at least five minutes of this to have an effect, and if the patient becomes distressed again during the consultation it can be repeated. The management of significant distress from acute anxiety, as marked by extreme and severe symptoms, is outlined in Box 5.

Patients suffering from chronic anxiety require a more comprehensive management approach. It is important to remember that anxiety often fluctuates, and GPs will almost certainly be seeing the patient at their worst. Resist the urge to write a prescription immediately, as many people are instantly reassured just by knowing from the GP that they have a recognisable and treatable condition.

There are also a number of online resources that GPs can refer patients to. These are listed in Box 6.

**Managing the doctor's anxiety**

As with all illnesses, patients with anxiety disorders visit their GP when their symptoms are severe. The GP may interpret this high level of anxiety as an urgent need to do something. A GP's anxiety can lead them to prescribe sedating medication (including sedating antidepressants,

antipsychotics, benzodiazepines or antihistamines) or overinvestigate for all possible differential diagnoses. Our anxiety as doctors comes from our uncertainty about being able to relieve a patient's distress, a mistaken sense that this needs to be done urgently and excessive concern not to miss a physical cause of anxiety. Unless the patient is expressing urgent suicidal ideation and intent, anxiety or even an acute panic attack does not cause serious harm. It is important for GPs to manage their anxiety about the patient's anxiety. Patients frequently feel reassured when a diagnosis and treatment plan are provided.

**Conclusion**

Anxiety disorders are common in adults, but often missed and poorly treated in clinical practice. The RANZCP Clinical Practice Guidelines for anxiety disorders provide updated and relevant information for clinicians regarding the management of anxiety disorders. We have drawn from the guidelines to provide GPs with practical clinical tools to help manage patients with panic disorder, SAD and GAD. The full guidelines concern the acute,

continuation and maintenance phases of treatment, and provide clear guidance to ensure the optimal management of patients with anxiety disorders. The advice provided in the clinical practice guidelines should equip GPs to navigate the complexities of managing these conditions. **MT**

**References**

A list of references is included in the online version of this article ([www.medicinetoday.com.au](http://www.medicinetoday.com.au)).

**COMPETING INTERESTS:** Professor Gavin Andrews has developed numerous digital cognitive-behavioural therapy programs on behalf of his employers UNSW Sydney and St Vincent's Hospital. He has no pecuniary interests in these programs.

Professor Philip Boyce has received speaker fees, consultancy fees and an educational grant from Servier Laboratories Australia Pty Ltd outside of the submitted work. He has also received speaker fees from Eli Lilly Australia Pty Ltd and Lundbeck Australia Pty Ltd outside of the submitted work.

Dr Christopher Gale is a member of the Cochrane Common Mental Disorders Group and contributor to Clinical Evidence 1999 to present.

Professor Ronald Rapee is the author of self-help books for child anxiety and adult SAD from which he receives royalties. He has also developed a manualised CBT program for child anxiety from which he receives no direct income.

Associate Professor Lisa Lampe has received payment for a presentation from Lundbeck Australia Pty Ltd outside of the submitted work.

Dr Greg Wilkins and Associate Professor Caroline Bell: None.

**ONLINE CPD JOURNAL PROGRAM**

**How do you recognise an anxiety disorder in an adult patient?**



Review your knowledge of this topic and earn CPD points by taking part in **MedicineToday's** Online CPD Journal Program. **Log in to** [www.medicinetoday.com.au/cpd](http://www.medicinetoday.com.au/cpd)

© ARONAMAY/ISTOCKPHOTO.COM  
MODEL USED FOR ILLUSTRATIVE PURPOSES ONLY

# Managing anxiety disorders in adults

**GREGORY WILKINS** BMed(Hons), FRANZCP; **GAVIN ANDREWS** MD, FRCPsych, FRANZCP; **CAROLINE BELL** BM BCH, MA, MRCPsych, MD  
**PHILIP BOYCE** MBBS MD FRANZCP; **CHRISTOPHER GALE** MB BS, MD, FRANZCP;  
**RONALD RAPEE** PhD(Psychology), MS (Psychology), BS (Psychology); **LISA LAMPE** MB BS, PhD, FRANZCP

## References

- Andrews G, Bell C, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. *Aust N Z J Psychiatry* 2018; 52: 1109-1172.
- van Dijk MK, Oosterbaan DB, Verbraak MJ, et al. Effectiveness of the implementation of guidelines for anxiety disorders in specialized mental health care. *Acta Psychiatr Scand* 2015; 132: 69-80.
- Beard C, Weisberg RB, Keller MB. Health-related quality of life across the anxiety disorders: findings from a sample of primary care patients. *J Anxiety Disord* 2010; 24: 559-564.
- Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. *Depress Anxiety* 2002; 16: 162-171.
- Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005; 62: 593-602.
- Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005; 62: 617-627.
- Wells EJ. Twelve-month prevalence. In: Browne MAO, Wells JE, Scott KM (eds). *Te Rau Hinengaro: the New Zealand mental health survey*. Wellington, New Zealand: Ministry of Health; 2006.
- Slade T, Johnston A, Oakley Browne MA, et al. 2007 National Survey of Mental Health and Wellbeing: methods and key findings. *Aust N Z J Psychiatry* 2009; 43: 594-605.
- McEvoy PM, Grove R, Slade T. Epidemiology of anxiety disorders in the Australian general population: findings of the 2007 Australian National Survey of Mental Health and Wellbeing. *Aust N Z J Psychiatry* 2011; 45: 957-967.
- Slade T, Johnston A, Teesson M, et al. *The Mental Health of Australians 2. Report on the 2007 National Survey of Mental Health and Wellbeing*. Canberra: Department of Health and Ageing; 2009.
- Lampe L. How common are the anxiety disorders. In: Boyce P, Harris A, Drobny J, et al. (eds). *The Sydney Handbook of Anxiety Disorders: a guide to the symptoms, causes and treatments of anxiety disorders*. Sydney: University of Sydney; 2015, 43-50.
- Roy-Byrne PP, Craske MG, Stein MB. Panic disorder. *Lancet* 2006; 368: 1023-1032.
- Swoboda H, Amering M, Windhaber J, et al. The long-term course of panic disorder - an 11 year follow-up. *J Anxiety Disord* 2003; 17: 223-232.
- Andersch S, Hetta J. A 15-year follow-up study of patients with panic disorder. *European Psychiatry* 2003; 18: 401-408.
- Cox BJ, Turnbull DL, Robinson JA, et al. The effect of avoidant personality disorder on the persistence of generalized social anxiety disorder in the general population: results from a longitudinal, nationally representative mental health survey. *Depress Anxiety* 2011; 28: 250-255.
- Ruscio AM, Brown TA, Chiu WT, Sareen J, Stein MB, Kessler RC. Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. *Psychol Med* 2008; 38: 15-28.
- Vriends N, Bolt OC, Kunz SM. Social anxiety disorder, a lifelong disorder? A review of the spontaneous remission and its predictors. *Acta Psychiatr Scand* 2014; 130: 109-122.
- Holaway RM, Rodebaugh TL, Heimberg RG. The epidemiology of worry and generalized anxiety disorder. In: Davey GC, Wells A (eds). *Worry and its psychological disorders: theory, assessment and treatment*. Hoboken, NJ: John Wiley and Sons Ltd; 2006.
- Yonkers KA, Dyck IR, Warshaw M, et al. Factors predicting the clinical course of generalised anxiety disorder. *Br J Psychiatry* 2000; 176: 544-549.
- Jameson JP, Blank MB. Diagnosis and treatment of depression and anxiety in rural and nonrural primary care: national survey results. *Psychiatr Serv* 2010; 61: 624-627.
- Stein MB, Sherbourne CD, Craske MG, et al. Quality of care for primary care patients with anxiety disorders. *Am J Psychiatry* 2004; 161: 2230-2237.
- Harris MG, Hobbs MJ, Burgess PM, et al. Frequency and quality of mental health treatment for affective and anxiety disorders among Australian adults. *Med J Aust* 2015; 202: 185-189.
- Boyce P, Harris A, Drobny J, et al. *The Sydney handbook of anxiety disorders: a guide to the symptoms, causes and treatments of anxiety disorders*. Sydney: The University of Sydney; 2015.
- Katerndahl DA, Realini JP. Where do panic attack sufferers seek care? *J Fam Pract* 1995; 40: 237-243.
- Deacon B, Lickel J, Abramowitz JS. Medical utilization across the anxiety disorders. *J Anxiety Disord* 2008; 22: 344-350.
- Fleet RP, Marchand A, Dupuis G, et al. Comparing emergency department and psychiatric setting patients with panic disorder. *Psychosomatics* 1998; 39: 512-518.
- Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. *Arch Gen Psychiatry* 2006; 63: 332-339.
- Comer JS, Blanco C, Hasin DS, et al. Health-related quality of life across the anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions (NESARC). *J Clin Psychiatry* 2011; 72: 43-50.
- Andrews G, Slade T, Issakidis C. Deconstructing current comorbidity: data from the Australian National Survey of Mental Health and Well-Being. *Br J Psychiatry* 2002; 181: 306-314.
- Brown TA, Campbell LA, Lehman CL, et al. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. *J Abnorm Psychol* 2001; 110: 585-599.
- Tyrer P, Seivewright H, Johnson T. The Nottingham study of neurotic disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. *Psychol Med* 2004; 34: 1385-1394.
- Moffitt TE, Harrington H, Caspi A, et al. Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years. *Arch Gen Psychiatry* 2007; 64: 651-660.
- Zhu B, Zhao Z, Ye W, et al. The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder. *J Nerv Ment Dis* 2009; 197: 136-139.
- Newby JM, Mewton L, Williams AD, Andrews G. Effectiveness of transdiagnostic Internet cognitive behavioural treatment for mixed anxiety and

- depression in primary care. *J Affect Disord* 2014; 165: 45-52.
35. Newby JM, McKinnon A, Kuyken W, et al. Systematic review and meta-analysis of transdiagnostic psychological treatments for anxiety and depressive disorders in adulthood. *Clin Psychol Rev* 2015; 40: 91-110.
36. Olatunji BO, Cisler JM, Tolin DF. A meta-analysis of the influence of comorbidity on treatment outcome in the anxiety disorders. *Clin Psychol* 2010; 30: 642-654.
37. McEvoy PM, Nathan P. Effectiveness of cognitive behavior therapy for diagnostically heterogeneous groups: a benchmarking study. *J Consult Clin Psychol* 2007; 75: 344-350.
38. Johnston L, Titov N, Andrews G, Dear BF, Spence J. Comorbidity and internet-delivered transdiagnostic cognitive behavioural therapy for anxiety disorders. *Cogn Behav Ther* 2013; 42: 180-192.
39. Norton PJ, Hayes SA, Springer JR. Transdiagnostic cognitive-behavioral group therapy for anxiety: outcome and process. *Int J Cogn Ther* 2008; 1: 266-279.
40. Chambless DL, Caputo GC, Bright P, et al. Assessment of fear of fear in agoraphobics: the body sensations questionnaire and the agoraphobic cognitions questionnaire. *J Consult Clin Psychol* 1984; 52: 1090-1097.
41. Manicavasagar V, Silove D, Wagner R, et al. A self-report questionnaire for measuring separation anxiety in adulthood. *Compr Psychiatry* 2003; 44: 146-153.
42. Reiss S, Peterson RA, Gursky DM, et al. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. *Behav Res Ther* 1985; 24: 1-8.
43. Oosthuizen P, Lambert T, Castle DJ. Dysmorphic concern: prevalence and associations with clinical variables. *Aust N Z J Psychiatry* 1998; 32: 129-132.
44. Garner D. EDI-3, Eating disorder inventory-3. Professional Manual. Lutz, FL: Psychological Assessment Resources, Inc; 2004.
45. Geer JH. The development of a scale to measure fear. *Behav Res Ther* 1965; 3: 45-53.
46. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006; 166: 1092-1097.
47. Chambless DL, Craig GC, Jasin SE, Gracely EJ, Williams C. The mobility inventory for agoraphobia. *Behav Res Ther* 1985; 25: 35-44.
48. Connor KM, Kobak KA, Churchill LE, et al. Mini-SPIN: a brief screening assessment for generalized social anxiety disorder. *Depress Anxiety* 2001; 14: 137-140.
49. Foa EB, Huppert JD, Leiberg S, et al. The obsessive-compulsive inventory: development and validation of a short version. *Psychol Assess* 2002; 14: 485-496.
50. Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. *Int Clin Psychopharmacol* 1995; 10: 73-81.
51. Ruggiero KJ, Del Ben K, Scotti JR, et al. Psychometric properties of the PTSD Checklist-Civilian Version. *J Trauma Stress* 2003; 16: 495-502.
52. Houck PR, Spiegel DA, Shear MK, et al. Reliability of the self-report version of the panic disorder severity scale. *Depress Anxiety* 2002; 15: 183-185.
53. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001; 16: 606-613.
54. Meyer TJ, Miller ML, Metzger RL, et al. Development and validation of the Penn State worry questionnaire. *Behav Res Ther* 1990; 28: 487-495.
55. Salkovskis PM, Rimes KA, Warwick HM, et al. The Health Anxiety Inventory: development and validation of scales for the measurement of health anxiety and hypochondriasis. *Psychol Med* 2002; 32: 843-853.
56. Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. *Behav Res Ther* 1998; 36: 455-470.
57. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. *J Trauma Stress* 2015; 28: 489-498.
58. Bovin MJ, Marx BP, Weathers FW, et al. Psychometric properties of the PTSD checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in veterans. *Psychol Assess* 2016; 28: 1379-1391.
59. Cohen J, Kanuri N, Kieschnick D, et al. Preliminary evaluation of the psychometric properties of the PTSD checklist for DSM-5. 48th Annual Convention of the Association of Behavior and Cognitive Therapies; Philadelphia, PA: 2014. DOI: 10.13140/2.1.4448.5444.
60. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. *Dialogues Clin Neurosci* 2017; 19: 2: 93-106.
61. Craske MG, Golinelli D, Stein MB, et al. Does the addition of cognitive behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary-care setting? *Psychol Med* 2005; 35: 1645-1654.
62. Andrews G, Crino R, Hunt C, et al. The treatment of anxiety disorders. New York: Cambridge University Press; 1994.
63. Andrews G, Creamer M, Crino R, et al. The treatment of anxiety disorders: clinician guides and patient manuals, 2nd ed. *J Can Acad Child Adolesc Psychiatry* 2003; 15: 46-47
64. Andrews G, Mahoney AE, Hobbs MJ, et al. Treatment of generalized anxiety disorder: therapist guides and patient manual. Oxford: Oxford University Press; 2016.
65. Cuijpers P, Sijbrandij M, Koole S, Huibers M, Berking M, Andersson G. Psychological treatment of generalized anxiety disorder: a meta-analysis. *Clin Psychol Rev* 2014; 34: 130-140.
66. Wiles N, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBaIT randomised controlled trial. *Lancet* 2013; 381: 375-384.
67. Dunlop BW, Kelley ME, Aponte-Rivera V, et al. Effects of patient preferences on outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study. *Am J Psychiatry* 2017; 174: 546-556.
68. Karyotaki E, Smit Y, Holdt Henningsen K, et al. Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. *J Affect Disord* 2016; 194: 144-152.
69. Craske MG, Stein MB. Anxiety. *Lancet* 2016; 388: 3048-3059.
70. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. *J Clin Psychiatry* 2010; 71: 839-854.
71. Cipriani A, Koesters M, Furukawa TA, et al. Duloxetine versus other anti-depressive agents for depression. *Cochrane Database Syst Rev* 2012; (10): CD006533.
72. Schueler YB, Koesters M, Wieseler B, et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. *Acta Psychiatr Scand* 2011; 123: 247-265.
73. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. *Arch Gen Psychiatry* 2006; 63: 332-339.
74. Cipriani A, Koesters M, Furukawa TA, et al. Duloxetine versus other anti-depressive agents for depression. *Cochrane Database Syst Rev* 2012; (10): CD006533.
75. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry, 12th Edition. New York, NY: John Wiley & Sons; 2015.
76. Stein DJ, Ahokas A, Marquez MS, et al. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. *J Clin Psychiatry* 2014; 75: 362-368
77. Andrews G, Dean K, Genderson M, et al. Management of mental disorders, 5th ed. Sydney: Amazon; 2014.
78. Gale CK, Millichamp J. Generalised anxiety disorder. *BMJ Clin Evid* 2011; 2011: 1002.
79. Williams T, Hattingh CJ, Kariuki CM, et al. Pharmacotherapy for social anxiety disorder (SAnD). *Cochrane Database Syst Rev* 2017; (10): CD001206.
80. Yerkes RM, Dodson JD. The relation of strength of stimulus to rapidity of habit-formation. *J Compar Neurol Psychol* 1908; 18: 459-482.
81. Hebb DO. Drives and the C.N.S. (conceptual nervous system). *Psychol Rev*. 1955; 62: 243-254.